key: cord-0707950-eepd5j1b authors: Chtita, Samir; Fouedjou, Romuald Tematio; Belaidi, Salah; Djoumbissie, Loris Alvine; Ouassaf, Mebarka; Qais, Faizan Abul; Bakhouch, Mohamed; Efendi, Mohammed; Tok, Tugba Taskin; Bouachrine, Mohammed; Lakhlifi, Tahar title: In silico investigation of phytoconstituents from Cameroonian medicinal plants towards COVID-19 treatment date: 2022-04-29 journal: Struct Chem DOI: 10.1007/s11224-022-01939-7 sha: e690867bfd3441b39caa4e5a04659466ea124c46 doc_id: 707950 cord_uid: eepd5j1b In silico studies performed on the metabolites of four Cameroonian medicinal plants with a view to propose potential molecules to fight against COVID-19 were carried out. At first, molecular docking was performed for a set of 84 selected phytochemicals with SARS-CoV-2 main protease (PDB ID: 6lu7) protein. It was further followed by assessing the pharmacokinetics and pharmacological abilities of 15 compounds, which showed low binding energy values. As the screening criteria for their ADMET properties were performed, only two compounds have shown suitable pharmacological properties for human administration which were shortlisted. Furthermore, the stability of binding of these compounds was assessed by performing molecular dynamics (MD) simulations. Based on further analysis through molecular dynamics simulations and reactivity studies, it was concluded that only the Pycnanthuquinone C (17) and the Pycnanthuquinone A (18) extracted from the Pycnanthus angolensis could be considered as candidate inhibitors for targeted protein. Indeed, we expect that these compounds could show excellent in vitro and in vivo activity against SARS-CoV-2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11224-022-01939-7. The respiratory system can be affected by illnesses ranging from acute infections such as pneumonia, bronchitis, influenza, and colds [1] ; chronic conditions such as asthma and sinusitis; and chronic obstructive pulmonary disease or symptoms such as cough [2] . The control of these diseases in developing countries depends closely on traditional medicine and more specifically on herbal remedies made from local medicinal plants [3, 4] . With this, tremendous expansion in the use of traditional medicine, in particular, herbal medicines has led to a plethora of ethnobotanical investigations conducted. These, later, have proven to be one of the most reliable approaches for the discovery of new drugs [5] . Although the Cameroonian flora is rich in medicinal plant species, only a few ethnobotanical studies have been identified, some plants for their use to treat respiratory diseases [6] . However, respiratory diseases present a high cost for both patients and for society [1] . In addition, secondary metabolites have shown great and rapid action than generic drugs in the treatment of many microbial and viral infections. Moreover, secondary metabolites of some medicinal plant species have been isolated, purified, and characterized. It appears that these plants are rich with secondary metabolites, which are known for their potential biological activities [7, 8] . The Cameroonian flora could therefore be a source of interesting secondary metabolites that could be used to fight against emerging infection including the SARS-CoV-2 and its novel variants. According to the World Health Organization, the worldwide situation update shows that from 31 December 2019 and as to the first week of October 2021, a total of 234 M cases (compare to 88.8 M cases in January) of COVID- 19 have been reported worldwide, including 4.8 M deaths (compare 1.9 M death cases in January), which show an increase of infected case (145.2 M) and number of death (2.9 M) during 9 months. In Africa, the situation is also alarming with 6 M cases and 0.15 M deaths; the five countries reporting the most high number of cases are South Africa (2.9 M), Morocco (0.9 M), Tunisia (0.7 M), Ethiopia (0.35 M), and Egypt (0.31) [9] . These statistics demonstrate that developing countries are not preserved and are inundated by this viral infectious disease, which now occupies an important place in the global incidence of transmissible diseases. Several attempts to manage this pandemic, despite all the advances made in modern and orthodox medicine, have posed mankind a lot of health consequences. Traditional medicine has consequently gained renewed interest in health care services. In addition, it is estimated that at least 25% of all modern medicines are derived directly or indirectly from medicinal plants, mainly through the application of modern technologies to traditional knowledge [10] . As a part of our ongoing bioprospection for anti-COVID-19 agents, we observed significant antiviral activity of some secondary metabolites isolated from common medicinal plants of the Asteraceae family [11] . Things that prompted us to carry out an in silico study on secondary metabolites isolated from others medicinal plants, based on ethnobotanical survey made in some Cameroonian villages. The study aims to promote the use of traditional pharmacopeia in a possible treatment of COVID-19 infection. The secondary metabolites collected from the identified species were used to generate ligands, which will be used for docking studies towards main target protein of SARS-CoV-2. Indeed, the interaction modes of 84 potential antiviral candidates were studied regarding the SARS-CoV-2 main protease (M pro ) protein using virtual screening, molecular docking, and molecular dynamics methods. The dataset of this study was constructed by gathering 84 phytochemicals from plants belonging to Cameroonian flora commonly used to treat respiratory infections. This set was collected as follows: 28 from Pycnanthus angolensis (Myristicaceae) [12] [13] [14] [15] [16] , 25 from Paullinia pinnata Linn (Sapindaceae) [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , 18 from Allanblackia monticola Staner L.C. (Guttiferae) [27] [28] [29] , and 13 from Alchornea cordifolia (Euphorbiaceae) [30] [31] [32] [33] (Table S1 ). The three-dimensional structures of these phytochemicals were obtained from the PubChem database. In order to perform molecular docking analysis, the structures of the 84 phytochemicals were optimized and converted into a single database format (SDF) using Discovery Studio 2020 software. Molecular docking study was performed for each compound of the set with main protease (M pro ) SARS-CoV-2 protein. Pharmacological and pharmacokinetic as well as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) proprieties of the studied compounds were also assessed by using SwissADME webserver (http:// www. swiss adme. ch) [34] . The SwissADME server was used to determine the ADME characteristics of the studied compounds and involving the assessment of the drug-like characteristics as well as their possible toxicity. Molecular docking is considered as one of the best computational methods used to highlight the bonding modes of molecules (ligands) with the targets [35] [36] [37] [38] , because of its ability to predict the conformation and mode of binding of the ligand to the receptor binding site. The three-dimensional structure of M pro protein bounded with N3 inhibitor was downloaded from Protein Data Bank (PDB ID: 6lu7). Firstly, before performing the molecular docking, the two proteins are prepared. The N3 inhibitor, water molecules, and all non-protein elements were removed, and hydrogen atoms were added to the structure. Next, the preparation of ligands that will be docked to proteins consists of adding hydrogen atoms to these ligands and optimizing their structure. The site of binding is defined as the volume occupied by the co-crystallized ligands in each of the receptors pocket. The protein and ligands as well as the ligand entry site into the protein pockets are prepared in the present work by using Discovery Studio 2016 software. In addition, Auto-Dock software (ADT) MGLTools 1.5.6 packages are used in the re-docking of the co-ligands with the receptor and in the docking of molecules for the 84 molecules with M pro SARS-CoV-2 protein. The 3D grid box dimensions were (20 × 20 × 20) Angstrom, with coordinates of x = −10.641, y = 11.847, and z = 68.346 to suit the binding site of removed N3 inhibitor. According to the results of recent molecular mechanics studies, Nelfinavir antiviral drug has been chosen to serve as a reference ligand with SARS-CoV-2 M pro (6lu7) protein in this study [39] [40] [41] [42] [43] . This work explores molecular docking in the identification of the most important active sites and in the analyzing of the interactions that occur between the docked molecules and the identified active site. The obtained results were evaluated according to the binding energy value, and the molecule with the lowest binding energy (best score) was considered as the best one that interacts with the target. Drug candidates should match many criteria as a basic step of drug discovery process in order to be considered as orally consumed drugs. Physicochemical properties (molecular weight, H bonding, heavy atoms, etc.), drug likeness properties (Lipinski et al. rule [44] , bioavailability), water solubility, pharmacokinetics, stability, and low cost of production are evaluated to make a point of view about adopting this drug or not. In the present study, SwissADME webserver was used to evaluate the ADMET properties of the top selected molecules. Examining the toxicological characteristics of the drug candidates and ensuring their safety are one of the most important stages to be followed to approve any novel drug. In this study, ProTox-II16 online web server (https:// tox-new. chari te. de/ protox_ II) was utilized to evaluate the toxicological properties of the selected molecules; this server predicts the values of oral toxicity, cytotoxicity, carcinogenicity, immunotoxicity, and mutagenicity. Some toxicity-related evaluations have also been added, such as minnow toxicity (MT), hepatotoxicity (HP), and skin sensitization (SS). All previous properties are fundamental for the access to toxicological risk. Compounds that have showed highest binding affinity were selected for further studies using molecular dynamics (MD) simulation. The MD simulation was performed using Gromacs-2018.1 packages with amber99sb-ILDN force field [45, 46] . The topology of both ligands was prepared using Antechamber packages in AmberTools19 [47] . The stability of the protein-ligand complexes for Mpro protein was studied using MD simulation. The protein and their complexes were solvated using TIP3P water model in triclinic boxes separately. All structures were neutralized by adding sodium or chlorine counter ions. The steepest minimization of 5000 steps was performed to remove weak Van der Waals contacts. All systems were then equilibrated for NVT and NPT for 1 ns each. The NVT equilibration was done at 300 K using V-rescale thermostat and the NPT equilibration was performed at 1.0 bar using Parrinello-Rahman barostat [48, 49] . The 100-ns MD simulation was carried out and a total of 10,000 frames of each system were saved at 10 ps intervals. All trajectories were subjected to PBC corrections before analysis using standard Gromacs utilities. One hundred frames from the trajectory of each complex were extracted from 60 to 100 ns for the MM-PBSA calculations [50] . Firstly, the co-crystallized ligand is re-docked into the active site to validate the accuracy of molecular docking. Based on the inhibitor N3 with 6lu7, the binding site was found to be mostly located in the hydrophobic cleft lined by the following amino acids: Glu166, Thr190, Gln189, Phe140, His41, His163, His164, His172, Gly143, Leu141, Leu167, Asn142, Met49, Met167, Met165, Pro168, and Ala191. It can be seen from Fig. 1 that there are eight hydrogen bond interactions with eight different amino acids, two with Glu166 and six with Phe140, Gly143, His163, His164, Gln189, and Thr190. There are two C-H interactions with Met165 and His172, and three hydrophobic Pi-alky interactions with Pro168, Ala191, and His41. Further inquiry indicates the presence of an Amide-Pi stacked interaction with Leu141 [51] . Then, molecular docking was performed for the 84 ligands with the M pro SARS-CoV-2 protein using Auto-Dock1.5.6 software. As it can be noticed from Table 1, molecules 40, 68, and 70 show the best binding affinity to the virus protein with binding energy of −8.5 kcal/ mol. Structural conformation analysis of the complexes (ligand-protein) was carried out to unpick the drug surface hotspot of the target. Molecular interaction types between protein and ligand were identified also; ligand-bounded amino acid residues were determined. Table 2 gather studied compounds showed had the best molecular docking scores with M pro SARS-CoV-2 protein. From the obtained outcomes of the molecular docking study, fifteen compounds have exhibited the best scores of binding energy values closely to the Nelfinavir (−8.2 kcal/ mol). These results allowed us support to suggest the 15 studied compounds as promising SARS-CoV-2 inhibitors. As depicted in Fig. 2C , Nelfinavir has shown the following interaction types with the M pro protein of SARS-CoV-2: two H-bonds with Gly339 residue and four hydrophobic interactions with Phen374, Trp436, Leu335, and Val367 residues. Although compound 18, obtained from Pycnanthus angolensis, was reported that it binds to 6lu7 protein with energy value of −8.3 kcal/mol; herein, it shows three H-bond interactions which maintain the stability of the complex. Two of them was formed with Gly143 amino acid residue and the third one with Ser144 amino acid residue of the M pro protein, at respective distances of 2.96 Å, 3.27 Å, and 2.87 Å (Fig. 2B) . Compound 17, isolated from Pycnanthus angolensis, exhibits a binding energy of −7.8 kcal/mol with the SARS-CoV-2 M pro protein. This compound interacts with the M pro protein through H-bond with His41 amino acid residue at distance of 2.24 Å and pi-anion interaction with Glu166 residue at distance of 4.14 Å ( Table 3 ). The interaction modes are illustrated in Fig. 2A . We can conclude that the following amino acid residues His41, Glu166, and Ser144 of the M pro protein contribute significantly in the stability of compounds 17 and 18. Drug candidates should possess favorable ADME properties and ideally non-toxic. Therefore, the designed compounds were evaluated of their ADME profile, including drug-likeness, partition coefficient, solubility, human intestinal absorption, penetration of the blood brain barrier (BBB), cytochrome P450 inhibition, and several other parameters using SwissADME. The results show among the 15 studied molecules, two molecules were capable to pass ADME profiling to the toxicity aspect study used ProTox-II webserver with reference of Globally Harmonized System (UN, 2013) . Drug-likeness is a key criterion in screening drug candidates at the earlier phase of drug discovery and development. This parameter can be described as a mean to correlate physicochemical aspect of a compound with its biopharmaceutical aspect in the human body, especially its influence in bioavailability of per oral route [52] . Two different rule-based filters, Lipinski et al. [44, 53] , were used to calculate the drug and lead likeness for the 15 selected compounds. The results exhibited that the compounds 29, 36, 37, 40, 48, 50, 68, and 70 have violated the understudy drug-likeness rules (Lipinski's criteria: less than 5 HBD, less than 10 HBA, a MW less than 500 g/ mol and log P not greater than 5 and Veber's criteria: TPSA should be less than 140 Å 2 and the NRB should be less than 10). These results suggest that these compounds have a low theoretical oral bioavailability according to the Lipinski's rule-of-five and bioavailability score value. Another important property of oral drugs is solubility in intestinal fluid, because insufficient solubility can limit intestinal absorption through the portal vein system. All of the compounds having low aqueous solubility level are shown in Table 4 , except for compounds 12, 15, 17, 18, 40, 48, 62, and 66 that have shown moderate solubility. The aqueous solubility (log S) of a compound significantly affects its absorption and distribution characteristics. The majority of the compounds identified have a low probability of being able to cross the BBB. In fact, only three compounds 12 have a good probability of being BBB permeates. Pan-Assay Interference Compounds (PAINS) are very familiar to medicinal chemists who have spent time fruitlessly trying to optimize these nonprogressible compounds [54] . Table 4 shows that three of the compounds tested return a PAINS alert (15, 17, and 68) . The cytochrome P450 (CYP) superfamily is important in drug elimination through metabolic biotransformation. Inhibition of these isoenzymes is certainly a major cause of pharmacokinetic-related drug interactions leading to toxic or unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites. Table 4 shows that all of compounds are found to be non-inhibitors of isoenzyme CYP1A2, except 12 and 66, and therefore the side effect (i.e., liver dysfunction) may be absent. CYP1A2 is expressed in the liver (10% of the total CYP content) and is responsible for the activation of aromatic and heterocyclic amines, PAHs, and many therapeutic drugs [55] . However, the compounds are predicted to be metabolized by CYP1A2, CYP2C19, CYP2C9, and CYP3A4 with more exceptions. Skin permeability (log kp) is an important parameter for the evaluation of drugs, which may require transdermal administration [56] . The more negative the log Kp, the less skin permeant is the molecule. Except for compounds 40 and 48, the log Kp measurements of all the tested compounds are found to be within the limits (−10.0 to −1.0). The toxicity prediction for the 7 compounds that did not violated Lipinski and Veber rules was based on different targets related to adverse drug reactions. The hepatotoxicity, carcinogenicity, mutagenicity, and cytotoxicity of the compounds have been determined [58] . Based on the results of ProTox II, it can be seen that the compound 66 is found to have mutagenicity. Compounds 12 and 62 are reported to be carcinogenicity. All compounds are not hepatotoxic and not cytotoxic (Table 5) . Active Inactive Inactive 1000 15 Inactive Inactive Inactive Inactive 340 17 Inactive Inactive Inactive Inactive 2000 18 Inactive Inactive Inactive Inactive 9000 41 Inactive Inactive Inactive Inactive 500 62 Inactive Active Inactive Inactive 2000 66 Inactive Inactive Active Inactive 3850 Prediction of LD50 using ProTox II showed that compounds 12, 17, 18, 62, and 66 are predicted to have oral LD50 value ranging from 800 to 9000 mg kg −1 in rat model and have non-toxic effect predicted. The results obtained from ADMET analysis reveal that compounds 17 and 18 are in good agreement with Lipinski's and Veber's rules with no violations; these two compounds have also acceptable ADMET properties. Compounds 17 and 18 could be orally administrated drug candidates. Moreover, compounds 17 and 18 were chosen to perform MD simulation study in order to investigate their stability on Mpro (6lu7) protein. The binding energy values observed for compounds 17 and 18 show that they possess good orientation shape with the active site of Mpro (6lu7) protein, through different interactions compared to chrysoeriol-7-O-β-D-glucuronopyranoside (BE = −8.0 kcal/mol) reported in our previous work [11] . The dynamic nature of the Mpro protein and their complexes were studied by simulating them in aqueous environment. The conformation exhibiting lowest biding energies was used in MD simulation studies. The initial analysis of trajectories for their stability was performed by calculating the root-mean square deviations (RMSD). The RMSD of each system was calculated with respect to their initial coordinates. The RMSD is presented in Fig. 3 . The RMSD of Mpro alone shows some instability during initial duration but became stable after 60 ns. A similar observation was found for Mpro-compound_17 and Mpro-compound_18 complexes. The average RMSD of Mpro, Mpro-compound_17 complex, and Mpro-compound_18 complex was found to be 0.234, 0.249, and 0.255 nm, respectively. The RMSD of all systems remained below 0.30 nm indicating a good stability of all systems. The stability of the protein in the absence of ligands was also assessed by calculating the root mean square fluctuations (RMSF). The RMSF of C α of all residues the protein is shown in Fig. 4 . The mass-weighted root mean square distance of a collection of atoms from their common center of mass is defined as radius of gyration (R g ). This is also an important parameter to be considered while studying the stability of proteins in aqueous systems [59] . Generally, the compact and globular proteins exhibit less variation in their radius of gyration compared to the expanded form of protein [60] . The R g of protein alone and their complexes are shown in Fig. 6 . As evident from the data, the R g of Mpro remained constant during the entire simulation time. A similar observation was found for Mpro-compound_18 complex, while there was a slight variation in R g of Mpro-compound_17 complex. These mean that all systems were stable during MD simulation. Moreover, the analysis of R g also inducted that Mpro protein did not undergo major conformational changes [61] . Solvent accessible surface is another important parameter for staying the stability of proteins through MD simulation. The SASA of Mpro protein and their complexes are shown in Fig. 7 . SASA of all systems was found to be persistent over the entire trajectory of simulation. This further validates the stability of complexes. Finally, the physicochemical parameters of all systems were also calculated. The total and potential energies of all systems is presented in Fig. 8 . Both these parameters were also found to be contact during simulation. The data finally validate the stability of all systems during MD simulation. The effect of binding of both ligands in the structure stability of protein was studied by determining the secondary structural motifs of the proteins. Each secondary structure component of Mpro protein is shown in Fig. 9 . The coils, β-sheet, β-bridge, bends, turns, and α-helix in Mpro were found to be 26.39, 25.99, 2.15, 7.20, 16.57 , and 17.78%, respectively. All these secondary structures of Mpro change insignificantly when were complexed with compound 17 or compound 18. The data showed that the presence of ligands did not affect the structural stability of both the proteins. The interaction between ligands and Mpro protein was studied by assessing the hydrogen bonds (Fig. 10) . There was existence of H-bonds both in Mpro-compound_17 complex and Mpro-compound_18 complex throughout the entire simulation period. The average number of hydrogen bonds forming between Mpro and compound 18 was slightly more than that of compound 17. In all complexes, there was existence of H-bonds throughout the simulation period. However, there were slight variations in the H-bond profiles, which may be due to the dynamical shift of the ligands at the binding site. Principal component analysis (PCA) is a standard statistical procedure to analyze the large-scale motion in biological macromolecules such as proteins and DNA. PCA is performed by reducing the dimensionality of data set without losing important information, which is characterized by eigenvectors [62] . PCA was done to explore the flexibility of Mpro protein and their complexes. The projection of eigenvectors in uncomplexed and complexed forms is presented in Fig. 11 . The data shows that Mpro alone and Mpro-compound_ 18 complex occupied a similar conformational space. However, Mpro-compound_17 complex occupied slightly more conformational space. This shows that the Mpro-compound_17 exhibited slightly more structural flexibility compared to Mpro alone and Mpro-compound_18 complex. The free energy landscapes (FEL) of Mpro protein and complexes were also plotted to explore the variations in the patterns of protein folding (Fig. 12) . The FEL shows that all systems reached energy minima in their respective landscapes. The lowest energy minima structures of the proteins were extracted to plot the respective Ramachandran plots. The Ramachandran plots of the protein and their complexes showed that almost all amino acids were found the favorable region (Fig. 13 ). The detailed insight regarding various binding energies involved for the interaction of both ligands with Mpro protein as done using MM-PBSA calculations. Non-covalent forces mainly stabilize the protein ligand interactions mostly, which include electrostatic, hydrophobic interactions, hydrogen bonds, and Van Der Waals force. These forces may either contribute positively or negatively to the overall binding [63] . For MM-PBSA calculations, 100 frames were extracted from 60 to 100 ns from the trajectory of each complex. The MM-PBSA binding energies are enlisted in Table 6 . The van Der Waals energy was found to be the major contributor in overall binding energy followed by the electrostatic energy. Moreover, there was also small contribution of SASA energy. However, polar solvation energy impaired the binding of both ligands to Mpro protein. The overall binding energy for interaction of compound 17 and compound 18 to Mpro was found to be −14.85 and −24.71 kcal mol −1 , respectively. It is interesting to note that the MM-PBSA binding energy of compounds 17 and 18 with the Mpro protein (6lu7) was more compared to the respective controls. This shows the stronger binding affinity of compounds 17 and 18 compared to the control N3 for 6lu7. The MM-PBSA data was further used to identify the key residues, which gave maximum contribution in the binding (Table 7) . For interaction of compound 17 with Mpro, Thr25, Leu27, Val42, Ile43, Thr45, Ser46, Met49, Arg60, Lys61, Leu141, Gly143, Cys145, His164, and Glu166 were the major energy contributors. Thr25, Leu27, Val42, Met49, Leu141, Cys145, Met165, Glu166, Asp187, and Gln189 were the key energy contributors for compound 18 Mpro interaction. Despite the huge effort made to control the current pandemic, the COVID-19 disease continues spreading throughout the globe. Nowadays, many vaccines are developed and are approved for emergency use even though most people of the world are not vaccinated yet, in particular, people belonging to developing country. It seems that the development of antiviral drugs could be a good strategy to fight against this continued pandemic. For this context, we have performed this in silico study, which aims to develop an inhibitor of both M pro (6lu7) SARS-CoV-2 protein. The study was conducted on 84 molecules collected from four medicinal plants belonging to Cameroonian flora. Among the 84 compounds, only 15 compounds have shown good binding affinity in the molecular docking analysis compared to the reference Data availability All data used in this work are private. The codes used in this work are not available. Étude ethnobotanique des plantes médicinales utilisées dans le traitement des infections du système respiratoire dans le plateau central marocain Épidémiologie descriptive de la bronchopneumopathie chronique obstructive (BPCO) en France La biodiversité face au développement des industries pharmaceutiques africaines Plantes médicinales utilisées par les populations bassa de la région de Douala au Cameroun Enquête ethnobotanique de six plantes médicinales maliennes -extraction, identification d'alcaloïdes -caractérisation, quantification de polyphénols: étude de leur activité antioxydante Étude floristique et ethnobotanique de la flore médicinale du Haut Atlas oriental (Haute Moulouya) Steroidal saponins from the leaves of Cordyline fruticosa L. A. Chev. and their cytotoxic and antimicrobial activity Antioxidant activities and chemical constituents of extracts from Cordyline fruticosa (Agavaceae) and Eriobotrya japonica (Rosaceae) Recherche de l'activité antibactérienne de quatre plantes médicinales camerounaises Abul Qais F (2021) Cameroonian medicinal plants as potential candidates of SARS-CoV-2 inhibitors Novel antihyperglycemic terpenoid-quinones from Pycnanthus angolensis Pycnanthuquinone C: a new terpenoid-quinone from Pycnanthus angolensis Antiplasmodial activity of lignans and extracts from Pycnanthus angolensis Pycnanthulignenes A−D, antimicrobial cyclolignene derivatives from the roots of Pycnanthus angolensis Pycnangloside: a new cerebroside from bark of Pycnanthus Angolensis Two new flavone glycosides from Paullinia pinnata Paullinoside A and paullinomide A: a new cerebroside and a new ceramide from leaves of Paullinia pinnata ChemInform 38 Two novel lupane triterpenoids from Paullinia pinnata L. with fibroblast stimulatory activity New triterpene isovanniloyl and antibacterial activity of constituents from the roots of Paullinia pinnata Linn (Sapindaceae) A novel triterpene from the roots of Paullinia pinnata: 6α-(3′-methoxy-4′-hydroxybenzoyl)-lup-20(29)-ene-3-one A new antimicrobial and radical-scavenging glycoside from Paullinia pinnata var. cameroonensis Antimicrobial steroidal saponin and oleanane-type triterpenoid saponins from Paullinia pinnata Paullinoside A and paullinomide A: a new cerebroside and a new ceramide from leaves of Paullinia pinnata A new cycloartane-type triterpene and a new eicosanoic acid ester from fruits of Paullinia pinnata L A prenylated xanthone from Allanblackia floribunda Antioxidant, antitumor and antimicrobial activities of the crude extract and compounds of the root bark of Allanblackia floribunda Polyphenols from Allanblackia floribunda seeds: identification, quantification and antioxidant activity Two xanthones and two rotameric (3⟶8) biflavonoids from the Cameroonian medicinal plant Allanblackia floribunda Oliv. (Guttiferae) In vitro antiplasmodial activity of extracts of Alchornea cordifolia and identification of an active constituent: ellagic acid Anti-inflammatory compounds from leaves and root bark of Alchornea cordifolia (Schumach. & Thonn.) Mull Arg Isolation, characterization and antibacterial activity screening of anthocyanidine glycosides from Alchornea Cordifolia Immunomodulatory activity of polysaccharides isolated from Alchornea cordifolia SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules Camphor, Artemisinin and sumac phytochemicals as inhibitors against COVID-19: computational approach, computers in biology and medicine 136:104758 Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation Abul Qais F (2021) Combined molecular docking and dynamics simulations studies of natural compounds as potent inhibitors against SARS-CoV-2 main protease A docking-scoring approach to identify effective antiviral 2,5-diaminoBenzophenone derivatives against the main protease of SARS-CoV-2 QSAR, molecular docking, and ADMET properties in silico studies of novel 4,5,6,7-Tetrahydrobenzo[D]-Thiazol-2-Yl derivatives derived from Dimedone as potent antitumor, C-Met Tyrosine Kinase Effect of nelfinavir stereoisomers on coronavirus main protease: molecular docking, molecular dynamics simulation and MM/GBSA study Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus Binding site analysis of potential protease inhibitors of COVID-19 using Auto Dock Virus disease Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings GROMACS: fast, flexible, and free Simmerling C (2015) ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB ACPYPE -AnteChamber PYthon Parser interface Canonical sampling through velocity rescaling Polymorphic transitions in single crystals: a new molecular dynamics method G_mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations Discovery of potent SARS-CoV-2 inhibitors from approved antiviral drugs via docking screening Quantifying the chemical beauty of drugs Molecular properties that influence the oral bioavailability of drug candidates Seven year itch: pan-assay interference compounds (PAINS) in 2017-utility and limitations The role of drug metabolizing enzymes in clearance Transdermal drug delivery by passive diffusion and iontophoresis: a review Molecular modelling of protein-carbohydrate interactions. docking of monosaccharides in the binding site of concanavalin A Large-scale prediction and testing of drug activity on side-effect targets Glyburide inhibits non-enzymatic glycation of HSA: an approach for the management of AGEs associated diabetic complications Cameroonian medicinal plants as potential candidates of SARS CoV-2 inhibitors 2021) Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease Biophysical insight into the binding mechanism of doxofylline to bovine serum albumin: an in vitro and in silico approach A comprehensive spectroscopic and computational investigation on the binding of the anti-asthmatic drug triamcinolone with serum albumin Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations The authors declare no competing interests.